AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
172.06
+0.57 (0.33%)
At close: Oct 26, 2026, 4:00 PM EDT
171.40
-0.66 (-0.38%)
After-hours: Oct 26, 2026, 7:53 PM EDT

AstraZeneca Revenue

AstraZeneca had revenue of $15.38B in the quarter ending June 30, 2026, with 6.41% growth. This brings the company's total for the last twelve months to $61.37B, up 8.61% year-over-year. In the year 2025, AstraZeneca had annual revenue of $58.74B with 8.63% growth.

Revenue (ttm)
$61.37B
Revenue Growth
+8.61%
P/S Ratio
4.34
Revenue / Employee
$645,279
Employees
95,100
Market Cap
267.05B

Revenue Chart

Revenue by Segment

By Segment

Chart
  • Oncology 25.62B 43.6%
  • BioPharmaceuticals: Cardiovascular, Renal & Metabolism PR (CVRM) 12.77B 21.7%
  • Rare Disease 9.13B 15.5%
  • BioPharmaceuticals: Respiratory & Immunology PR (R&I) 8.87B 15.1%
  • BioPharmaceuticals Infectious Disease PR (ID) 1.27B 2.2%
  • Other Medicines 988.00M 1.7%
  • Collaboration 99.00M 0.2%

By Geography

Chart
  • The Americas 27.56B 46.9%
  • Rest of Europe 13.46B 22.9%
  • Asia, Africa & Australasia 13.37B 22.8%
  • UK 4.36B 7.4%
Fiscal year ended Dec 31, 2025 See the full AstraZeneca breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202558.74B4.67B8.63%
Dec 31, 202454.07B8.26B18.03%
Dec 31, 202345.81B1.46B3.29%
Dec 31, 202244.35B6.93B18.53%
Dec 31, 202137.42B10.80B40.58%
Dec 31, 202026.62B2.23B9.16%
Dec 31, 201924.38B2.29B10.38%
Dec 31, 201822.09B-375.00M-1.67%
Dec 31, 201722.47B-537.00M-2.33%
Dec 31, 201623.00B-1.71B-6.90%
Dec 31, 201524.71B-1.84B-6.93%
Dec 31, 201426.55B741.00M2.87%
Dec 31, 201325.81B-2.17B-7.75%
Dec 31, 201227.97B-5.62B-16.72%
Dec 31, 201133.59B322.00M0.97%
Dec 31, 201033.27B465.00M1.42%
Dec 31, 200932.80B1.20B3.81%
Dec 31, 200831.60B2.04B6.91%
Dec 31, 200729.56B3.08B11.65%
Dec 31, 200626.48B2.53B10.54%
Dec 31, 200523.95B--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Johnson & Johnson99.34B
Merck & Co.66.57B
AbbVie64.39B
Pfizer63.70B
Novartis AG56.69B
Sanofi55.89B
Novo Nordisk50.34B
Bristol-Myers Squibb Company49.19B
Revenue Rankings